1. Academic Validation
  2. State-selective small molecule degraders that preferentially remove aggregates and oligomers

State-selective small molecule degraders that preferentially remove aggregates and oligomers

  • Nat Commun. 2025 Nov 25;16(1):10486. doi: 10.1038/s41467-025-65454-z.
Jakub Luptak # 1 2 Dean Clift # 1 Aamir Mukadam 3 Jonathan Benn 3 Tyler Rhinesmith 1 Stephen H McLaughlin 1 Amy C Dodds 4 Jerson E Lapetaje 4 Matylda Sczaniecka-Clift 1 David J France 4 William A McEwan 3 Leo C James 5
Affiliations

Affiliations

  • 1 MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, UK.
  • 2 Protein Sciences, Structure, and Biophysics, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.
  • 3 UK Dementia Research Institute at the University of Cambridge, Department of Clinical Neurosciences, Hills Road, Cambridge, UK.
  • 4 School of Chemistry, Joseph Black Building, University of Glasgow, Glasgow, UK.
  • 5 MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, UK. [email protected].
  • # Contributed equally.
Abstract

TRIM21 is a unique E3 Ligase that uses a clustering-based activation mechanism to degrade complex multimeric substrates. This activity underpins the targeted protein degradation technology Trim-Away and genetically encoded degraders that selectively target aggregated Tau Protein and prevent tauopathy. Here we describe small molecules that mimic TRIM21's natural epitope and function as either effective inhibitors or potent and selective degraders called TRIMTACs. TRIMTACs mediate degradation as rapidly as PROTACs but can also selectively degrade specific protein pools depending on assembly state. We demonstrate the utility of this state-specific degradation by selectively removing the pro-inflammatory signalling protein MyD88 when assembled into the Myddosome and the cell-death protein RIPK3 when polymerised into the Necrosome. We further show that TRIMTACs can inhibit seeded tau aggregation under conditions where a PROTAC is ineffective. These results highlight that TRIM21's clustering-based activation can be exploited by small molecule degraders to carry out state-selective degradation of therapeutic targets.

Figures
Products